Article
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
Leukemia - 1 Oct 2013
Jovanovic J V, Ivey A, Vannucchi A M, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden B A, Jansen J H, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy M J, Schwemmers S, Gruender A, Kelley T W, Reading S, Pancrazzi A, McMullin M F, Pahl H L, Cross N C P, Harrison C N, Prchal J T, Chomienne C, Kiladjian J J, Barbui T, Grimwade D
Abstract excerpt
Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, affecting clinical utility. Therefore, we established a network of 12 laboratories from seven...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.